Urinary Biomarker in Bladder Cancer at Present Time
Korean Journal of Urological Oncology
; : 183-193, 2020.
Article
in Ko
| WPRIM
| ID: wpr-902522
Responsible library:
WPRO
ABSTRACT
Current standard diagnostic modality of bladder cancer is cystoscopy with/without urine cytology from patient’s voided urine. Considering several cystoscopic disadvantages such as symptomatic invasiveness and operatordependency, urinary cytology is an asymptomatic, noninvasive tool to detect exfoliated tumor cell in the urine samples. Various targeting molecules have been suggested to detect cancer cells in the urine beside the present urine cytology which has a limited diagnostic power of detection cancer cells. To augment the accuracy of diagnostic power, various supplementary urine biomarkers have been approved and under investigation in these days with different mechanisms and different targets. In this review article, we are going to discuss some urinary biomarkers approved by the U.S. Food and Drug Administration (FDA) and other non-FDA approved potential urinary markers in bladder cancer.
Full text:
1
Database:
WPRIM
Language:
Ko
Journal:
Korean Journal of Urological Oncology
Year:
2020
Document type:
Article